Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combined Amneal adds bevacizumab and Gemini

Executive Summary

Amneal has struck a licensing deal with Mabxience for exclusive US rights to biosimilar Avastin (bevacizumab) and has acquired branded player and hybrid 505(b)(2) specialist Gemini Laboratories for US$117 million, at the same time as announcing the completion of its merger with Impax, creating the “fifth-largest US generics player”.

You may also be interested in...

Revamped Amneal Would Consider A Transformational Deal

Amneal’s new management team is open to negotiating a major transaction, even as it looks to restore organic growth through a greater focus on differentiated generic and hybrid products.

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Amneal Has The Firepower To Pursue Injectables Deals

With integration of the merger between Amneal and Impax largely completed, the US-focused group is on the look-out for deals to boost its generic injectables portfolio.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts